FSUE Moscow Endocrine Plant took part in the annual forum and exhibition Biotechmed 2019. The event was traditionally held with the support of the Ministry of Industry and Trade of the Russian Federation, the Ministry of Health of the Russian Federation, Rostech State Corporation, and the Administration of the Krasnodar Territory. The key topics of the discussion at Biotechmed 2019 were the implementation of the current stage of the National Healthcare project, the development of the digital circuit of the healthcare system, international cooperation and the export of pharmaceutical and medical products. The forum program in total included more than 20 sessions, two plenary discussions, lectures for students and young scientists.
At the first Biotechmed 2019 Plenary Meeting, held on September 16, 2019, Teva and the FSEU Moscow Endocrine Plant signed a Memorandum of Intent on the implementation of actions aimed at the introduction to the market of the Russian Federation of Trizenox (arsenic trioxide) for the treatment of acute promyelocytic leukemia in adult patients with resistance to retinoids and chemotherapeutic drugs.
According to the Memorandum, the parties will study the possibility of transferring from Teva to the FSUE Moscow Endocrine Plant of the rights of the holder of the Registration Certificate and the rights to import, sell, distribute and also to promote the drug at the territory of the Russian Federation.
The aim of the partnership is to ensure the availability of the drug Trizenox (arsenic trioxide) intended for remission in patients with acute promyelocytic leukemia in the Russian Federation. Acute promyelocytic leukemia (ARF) is a rare, orphan oncological disease and amounts to 5-15% 2 of all cases of acute myeloid leukemia.
“We observe the increase in the demand of the Russian health care system for effective high-quality orphan drugs. Trizenox is a really important drug that will provide an opportunity for Russian patients to receive timely treatment with proven clinical efficacy and good tolerance of such a rare oncology disease as acute promyelocytic leukemia. The signing of the Memorandum of Intent is a strategically important step for the company, and we will make every effort to ensure the timely transfer of rights and improve the provision of our patients with the drug,” - said Eric Roche, the Director General of Teva Russia.
“I am sure that cooperation with one of the leaders in the global pharmaceutical industry will allow us to combine infrastructural capabilities and direct them to expand the ability of patients with rare diseases to receive the necessary therapy,” said Mikhail Fonarev, the Director General of FSEU Moscow Endocrine Plant.
Comment type is not specified in the component properties.